USO 23156
Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta TCell Infusions in Combination with Low Dose Radiotherapy in Subjects with Stage 4 Metastatic Non-Small Cell Lung Cancer.(DELTACEL-01)
Disease Types: Cellular & Gene
Eligibility Requirements:
- Signed and dated informed consent form.
- Male or female, > 18 years old.
- Minimum body weight of 50 kilograms (kg).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically or cytologically confirmed stage 4 metastatic NSCLC
- Progressed on at least 2 lines of SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors.
- Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.
- At least one measurable target lesion based on RECIST v1.1
Available at: